Sansure Biotech Inc.

Shanghai Stock Exchange 688289.SS

Sansure Biotech Inc. Gross Profit Margin for the year ending December 31, 2023: 71.54%

Sansure Biotech Inc. Gross Profit Margin is 71.54% for the year ending December 31, 2023, a 21.59% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Sansure Biotech Inc. Gross Profit Margin for the year ending December 31, 2022 was 58.83%, a -17.91% change year over year.
Sansure Biotech Inc. Gross Profit Margin for the year ending December 31, 2021 was 71.67%, a -10.00% change year over year.
Sansure Biotech Inc. Gross Profit Margin for the year ending December 31, 2020 was 79.64%, a 22.22% change year over year.
Sansure Biotech Inc. Gross Profit Margin for the year ending December 31, 2019 was 65.16%, a 11.45% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Shanghai Stock Exchange: 688289.SS

Sansure Biotech Inc.

CEO	Mr. Lizhong Dai
IPO Date	Aug. 28, 2020
Location	China
Headquarters	No. 680, Lusong Road
Employees	2,006
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Sansure Biotech Inc. develops and sells upstream nucleic acid extraction kits, real time PCR diagnostic and research kits, and fluorescence systems in China and internationally. The company offers novel coronavirus nucleic acid diagnostic kits; viral hepatitis and AIDS, blood screening, and extraction kits; cancer-related biomarkers; and kits for respiratory tract diseases, STDs, digestive tract diseases, prenatal and postnatal care, and genetic diseases, as well as instruments and other consumables. It serves hospitals and laboratories. The company was founded in 2008 and is based in Changsha, China.

Key trends

Past 5 years